Advertisement
Screener

Erasca, Inc. (ERAS) Current Assets

2.8 / 5 stars · 68/120 Roast Me

Erasca, Inc. Current Assets

Erasca, Inc. (ERAS) had Current Assets of $278.44 million as of 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Balance Sheet › Assets › Assets, Current

us-gaap:AssetsCurrent · last filed 2026-08-11

  • 2026-06-30: Assets, Current $278.44M.
  • 2026-03-31: Assets, Current $253.78M.
  • 2025-12-31: Assets, Current $286.24M.
  • 2025-09-30: Assets, Current $299.93M.
Period endAssets, Current
2026-06-30$278.44M
10-Q · filed 2026-08-11
2026-03-31$253.78M
10-Q · filed 2026-05-11
2025-12-31$286.24M
10-Q · filed 2026-08-11
2025-09-30$299.93M
10-Q · filed 2025-11-12
2025-06-30$310.66M
10-Q · filed 2025-08-12
2025-03-31$314.62M
10-Q · filed 2025-05-13
2024-12-31$308.79M
10-K · filed 2026-03-12
2024-09-30$330.17M
10-Q · filed 2024-11-12
2024-06-30$418.00M
10-Q · filed 2024-08-12
2024-03-31$306.62M
10-Q · filed 2024-05-08
2023-12-31$320.68M
10-K · filed 2025-03-20
2023-09-30$305.97M
10-Q · filed 2023-11-09
2023-06-30$323.85M
10-Q · filed 2023-08-10
2023-03-31$397.88M
10-Q · filed 2023-05-15
2022-12-31$444.50M
10-K · filed 2024-03-27
2022-09-30$365.75M
10-Q · filed 2022-11-09
2022-06-30$381.42M
10-Q · filed 2022-08-11
2022-03-31$403.37M
10-Q · filed 2022-05-12
2021-12-31$420.02M
10-K · filed 2023-03-23
2021-09-30$492.31M
10-Q · filed 2021-11-10
2021-06-30$197.29M
10-Q · filed 2021-08-26
2020-12-31$119.99M
10-K · filed 2022-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51